137 related articles for article (PubMed ID: 1705812)
21. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
[TBL] [Abstract][Full Text] [Related]
22. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
[TBL] [Abstract][Full Text] [Related]
23. IMP dehydrogenase and action of antimetabolites in human cultured blast cells.
Yamada Y; Goto H; Yoshino M; Ogasawara N
Biochim Biophys Acta; 1990 Mar; 1051(3):209-14. PubMed ID: 1968764
[TBL] [Abstract][Full Text] [Related]
24. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS
Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin.
Olah E; Csokay B; Prajda N; Kote-Jarai Z; Yeh YA; Weber G
Anticancer Res; 1996; 16(5A):2469-77. PubMed ID: 8917337
[TBL] [Abstract][Full Text] [Related]
26. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
[TBL] [Abstract][Full Text] [Related]
27. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
Jayaram HN; Zhen W; Gharehbaghi K
Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
[TBL] [Abstract][Full Text] [Related]
28. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
29. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the signal transduction program by drugs.
Weber G; Shen F; Prajda N; Yang H; Li W; Yeh A; Csokay B; Olah E; Look KY
Adv Enzyme Regul; 1997; 37():35-55. PubMed ID: 9381980
[TBL] [Abstract][Full Text] [Related]
31. Selective sensitivity to tiazofurin of human leukemic cells.
Jayaram HN; Pillwein K; Nichols CR; Hoffman R; Weber G
Biochem Pharmacol; 1986 Jun; 35(12):2029-32. PubMed ID: 3718544
[TBL] [Abstract][Full Text] [Related]
32. IMP dehydrogenase and GTP as targets in human leukemia treatment.
Weber G
Adv Exp Med Biol; 1991; 309B():287-92. PubMed ID: 1685859
[No Abstract] [Full Text] [Related]
33. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
34. Synergistic action of tiazofurin with hypoxanthine and allopurinol in human neuroectodermal tumor cell lines.
Szekeres T; Schuchter K; Chiba P; Ressmann G; Lhotka C; Gharehbaghi K; Szalay SM; Pillwein K
Biochem Pharmacol; 1993 Dec; 46(11):1903-7. PubMed ID: 7903533
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of tiazofurin in human colon carcinoma HT-29.
Zhen W; Jayaram HN; Weber G
Cancer Invest; 1992; 10(6):505-11. PubMed ID: 1358409
[TBL] [Abstract][Full Text] [Related]
36. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
37. Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells.
Kharbanda SM; Miyazaki K; Takeyama H; Sherman ML; Spriggs DR; Carney WP; Kufe DW
Cancer Commun; 1989; 1(3):191-7. PubMed ID: 2639729
[TBL] [Abstract][Full Text] [Related]
38. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
39. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
[TBL] [Abstract][Full Text] [Related]
40. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
